Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.WuXi PharmaTech (Cayman) has entered into an agreement with Johnson & Johnson Pharmaceutical Research & Development (J&JPRD), a division of Janssen Pharmaceutica (Janssen), to collaborate in the area of preclinical services.
Subscribe to our email newsletter
As per the agreement, WuXi PharmaTech is expected to become a provider of toxicology and other non-clinical services to Janssen. In addition, Janssen will provide training and other services, reimbursed by WuXi, to establish the GLP quality system and technical capabilities to meet the international standards at WuXi’s toxicology facility in Suzhou, China.
The facility is currently conducting non-GLP toxicology services, as well as client-sponsored GLP validation studies to demonstrate its growing capabilities. WuXi PharmaTech said that it would remain on target to begin offering GLP toxicology studies by mid-2010.
Ge Li, chairman and CEO of WuXi PharmaTech, said: “We are pleased to establish this new partnership with Janssen, which builds on our existing agreement to provide them with integrated pharmaceutical R&D services.
“We believe that China, with its high-quality scientific talent and favorable cost structure, is destined to become a major center for toxicology services over the next decade.”